Search Page

1

In Vitro-to-In Vivo Extrapolation of Transporter Inhibition Data for Drugs Approved by the US Food and Drug Administration in 2018.

Yu J, Ragueneau-Majlessi I. Yu J, et al. Among authors: Ragueneau-Majlessi I. Clin Transl Sci. 2020 Jan 25. doi: 10.1111/cts.12750. Online ahead of print. Clin Transl Sci. 2020. PMID: 31981398

Cite

Share

2

New antiepileptic drugs: review on drug interactions.

Hachad H, Ragueneau-Majlessi I, Levy RH. Hachad H, et al. Ther Drug Monit. 2002 Feb;24(1):91-103. doi: 10.1097/00007691-200202000-00016. Ther Drug Monit. 2002. PMID: 11805729 Review.

Cite

Share

3

Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database.

Levy RH, Hachad H, Yao C, Ragueneau-Majlessi I. Levy RH, et al. Curr Drug Metab. 2003 Oct;4(5):371-80. doi: 10.2174/1389200033489325. Curr Drug Metab. 2003. PMID: 14529369 Review.

Cite

Share

4

Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.

Zhang H, Ragueneau-Majlessi I, Levy RH. Zhang H, et al. Drug Metab Lett. 2009 Dec;3(4):287-9. doi: 10.2174/187231209790218136. Drug Metab Lett. 2009. PMID: 19995331

Cite

Share

5

A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database.

Hachad H, Ragueneau-Majlessi I, Levy RH. Hachad H, et al. Hum Genomics. 2010 Oct;5(1):61-72. doi: 10.1186/1479-7364-5-1-61. Hum Genomics. 2010. PMID: 21106490 Free PMC article.

Cite

Share

6

Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Isoherranen N, Lutz JD, Chung SP, Hachad H, Levy RH, Ragueneau-Majlessi I. Isoherranen N, et al. Chem Res Toxicol. 2012 Nov 19;25(11):2285-300. doi: 10.1021/tx300192g. Epub 2012 Sep 27. Chem Res Toxicol. 2012. PMID: 22823924 Free PMC article. Review.

Cite

Share

7

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM. Vieira ML, et al. Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18. Clin Pharmacol Ther. 2014. PMID: 24048277

Cite

Share

8

Drug disposition and drug-drug interaction data in 2013 FDA new drug applications: a systematic review.

Yu J, Ritchie TK, Mulgaonkar A, Ragueneau-Majlessi I. Yu J, et al. Drug Metab Dispos. 2014 Dec;42(12):1991-2001. doi: 10.1124/dmd.114.060392. Epub 2014 Sep 30. Drug Metab Dispos. 2014. PMID: 25271211 Review.

Cite

Share

9

Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.

Lee CA, O'Connor MA, Ritchie TK, Galetin A, Cook JA, Ragueneau-Majlessi I, Ellens H, Feng B, Taub ME, Paine MF, Polli JW, Ware JA, Zamek-Gliszczynski MJ. Lee CA, et al. Drug Metab Dispos. 2015 Apr;43(4):490-509. doi: 10.1124/dmd.114.062174. Epub 2015 Jan 13. Drug Metab Dispos. 2015. PMID: 25587128 Review.

Cite

Share

10

Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model Verification.

Sager JE, Yu J, Ragueneau-Majlessi I, Isoherranen N. Sager JE, et al. Drug Metab Dispos. 2015 Nov;43(11):1823-37. doi: 10.1124/dmd.115.065920. Epub 2015 Aug 21. Drug Metab Dispos. 2015. PMID: 26296709 Free PMC article. Review.

Cite

Share